A Study in Patients With Advanced Cancers
Primary Purpose
Advanced Cancer, Advanced Solid Tumor, Cancer
Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
BIO-106
Pembrolizumab
Sponsored by

About this trial
This is an interventional treatment trial for Advanced Cancer
Eligibility Criteria
Key Inclusion Criteria:
- Patients histologically or cytologically documented, locally advanced or metastatic solid tumor.
- Disease progression confirmed by imaging or other objective evidence after having received standard treatment; or patients with refractory solid tumors who cannot tolerate standard treatment or have contraindications to standard treatment.
- Measurable disease as determined by RECIST v.1.1 or bone only disease.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Key Exclusion Criteria:
- History of severe hypersensitivity to any ingredient of the study drug(s), including pembrolizumab or other monoclonal antibody.
Impaired cardiac function or history of clinically significant cardiac disease
- Human Immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection.
- Active SARS-CoV-2 infection.
- Untreated central nervous system (CNS), epidural tumor or metastasis, or brain metastasis.
Other protocol defined inclusion/exclusion criteria may apply.
Sites / Locations
- NEXT Oncology AustinRecruiting
- University of Texas MD Anderson Cancer CenterRecruiting
- NEXT Oncology VirginiaRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Single agent BIO-106
Combination BIO-106 plus pembrolizumab
Arm Description
Escalating doses followed by expansion targeting advanced cancers
Escalating doses followed by expansion targeting advanced cancers
Outcomes
Primary Outcome Measures
Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Phase 1)
Escalation period
Incidence and nature of dose-limiting toxicities (DLTs) - (Phase 1)
Escalation period
Maximum tolerable dose (MTD) or a tolerated dose below MTD - (Phase 1)
Escalation period
Anti-tumor activity by objective response rate (ORR), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS) - (Phase 2)
Expansion period
Secondary Outcome Measures
Anti-tumor activity by objective response rate (ORR), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS) - (Phase 1)
Escalation Period
Incidence of adverse event of special interest (AESI) - (Phase 2)
Expansion period
Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Phase 2)
Expansion period
PK (Cmax) of BIO-106 - (Phase 1/2)
Escalation and expansion periods
PK (AUC) of BIO-106 - (Phase 1/2)
Escalation and expansion periods
Incidence of anti-BIO-106 antibodies - (Phase 1/2)
Escalation and expansion periods
Full Information
NCT ID
NCT05320588
First Posted
April 2, 2022
Last Updated
July 15, 2022
Sponsor
BiOneCure Therapeutics Inc.
1. Study Identification
Unique Protocol Identification Number
NCT05320588
Brief Title
A Study in Patients With Advanced Cancers
Official Title
A Phase 1/2 Study of BIO-106 As Monotherapy or In Combination With Pembrolizumab in Patients With Advanced Cancers (StarBridge-1)
Study Type
Interventional
2. Study Status
Record Verification Date
July 2022
Overall Recruitment Status
Recruiting
Study Start Date
March 25, 2022 (Actual)
Primary Completion Date
April 2024 (Anticipated)
Study Completion Date
April 2027 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
BiOneCure Therapeutics Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.
Detailed Description
This is an open-label, Phase 1/2, first-in-human (FIH), multiple ascending dose and dose-expansion study of BIO-106 administered as monotherapy and in combination with pembrolizumab. Phase 1 will define the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of BIO-106 that can be advanced to Phase 2. Phase 2 will define the preliminary efficacy of these regimens in the setting of advanced solid tumors with high unmet medical needs.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Model Description
Multiple ascending dose and dose-expansion of BIO-106 administered as a single agent or in combination with pembrolizumab.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
332 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Single agent BIO-106
Arm Type
Experimental
Arm Description
Escalating doses followed by expansion targeting advanced cancers
Arm Title
Combination BIO-106 plus pembrolizumab
Arm Type
Experimental
Arm Description
Escalating doses followed by expansion targeting advanced cancers
Intervention Type
Drug
Intervention Name(s)
BIO-106
Intervention Description
BIO-106 is a novel antibody-drug conjugate (ADC) that targets the human trophoblast cell surface antigen 2 (Trop-2)
Intervention Type
Drug
Intervention Name(s)
Pembrolizumab
Other Intervention Name(s)
Keytruda
Intervention Description
Programmed death receptor-1 (PD 1)-blocking antibody
Primary Outcome Measure Information:
Title
Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Phase 1)
Description
Escalation period
Time Frame
1 year
Title
Incidence and nature of dose-limiting toxicities (DLTs) - (Phase 1)
Description
Escalation period
Time Frame
up to 21 days
Title
Maximum tolerable dose (MTD) or a tolerated dose below MTD - (Phase 1)
Description
Escalation period
Time Frame
1 year
Title
Anti-tumor activity by objective response rate (ORR), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS) - (Phase 2)
Description
Expansion period
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Anti-tumor activity by objective response rate (ORR), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS) - (Phase 1)
Description
Escalation Period
Time Frame
1 year
Title
Incidence of adverse event of special interest (AESI) - (Phase 2)
Description
Expansion period
Time Frame
2 years
Title
Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Phase 2)
Description
Expansion period
Time Frame
2 years
Title
PK (Cmax) of BIO-106 - (Phase 1/2)
Description
Escalation and expansion periods
Time Frame
2 years
Title
PK (AUC) of BIO-106 - (Phase 1/2)
Description
Escalation and expansion periods
Time Frame
2 years
Title
Incidence of anti-BIO-106 antibodies - (Phase 1/2)
Description
Escalation and expansion periods
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria:
Patients histologically or cytologically documented, locally advanced or metastatic solid tumor.
Disease progression confirmed by imaging or other objective evidence after having received standard treatment; or patients with refractory solid tumors who cannot tolerate standard treatment or have contraindications to standard treatment.
Measurable disease as determined by RECIST v.1.1 or bone only disease.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Key Exclusion Criteria:
History of severe hypersensitivity to any ingredient of the study drug(s), including pembrolizumab or other monoclonal antibody.
Impaired cardiac function or history of clinically significant cardiac disease
Human Immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection.
Active SARS-CoV-2 infection.
Untreated central nervous system (CNS), epidural tumor or metastasis, or brain metastasis.
Other protocol defined inclusion/exclusion criteria may apply.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
BiOneCure Therapeutics Inc.
Phone
(240) 912-9101
Email
Starbridge-1@bionecure.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
BiOneCure Clinical Development
Organizational Affiliation
BiOneCure Therapeutics Inc.
Official's Role
Study Director
Facility Information:
Facility Name
NEXT Oncology Austin
City
Austin
State/Province
Texas
ZIP/Postal Code
78758
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cynthia DeLeon
Phone
210-580-9521
Email
cdeleon@nextoncology.com
Facility Name
University of Texas MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Funda Meric-Bernstam, MD
Phone
832-483-8248
Email
fmeric@mdanderson.org
Facility Name
NEXT Oncology Virginia
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Malaika Komtangi
Phone
210-580-9500
Email
mkomtangi@nextoncology.com
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
A Study in Patients With Advanced Cancers
We'll reach out to this number within 24 hrs